下一个

自动播放

Highlights in skin cancer at ESMO 2022

2 意见 • 07/17/23
分享
嵌入
administrator
administrator
订户
0

Dirk Schadendorf, MD, University Hospital Essen, Essen, Germany, comments on important trials in the field of skin cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress, including results of the Phase II IMMUNED trial (NCT02523313) of adjuvant nivolumab alone or in combination with ipilimumab versus placebo in stage IV melanoma. Prof. Schadendorf additionally highlights novel trials investigating treatments for Merkel cell carcinoma. This interview took place at the ESMO 2022 Congress in Paris, France.

显示更多
0 注释 sort 排序方式
脸书评论

下一个

自动播放